Literature DB >> 36118410

Outcome of Patients with Cervical and Vaginal Stump Carcinomas Treated with More Conservative Surgical Approaches: a 9-Year Experience of a Tertiary Oncology Center.

Mohamed Hegazy1, Ashraf Khater1, Mohamed Awad2, Sherif Kotb1, Waleed Elnahas1, Sameh Roshdy1, Osama Eldamshety1, Fayez Shahatto1, Omar Farouk1, Emadeldeen Hamed1, Refaat Hegazi3, Ola T Abdel Dayem4, Anas M Gamal5.   

Abstract

The surgical management of stump carcinoma includes the gold standard pelvic exenteration and more conservative approaches. This study aimed to investigate the outcome among a cohort of vaginal and cervical stump carcinomas that were treated with an intent of organ preservation. This is a prospective study of 60 patients with a biopsy confirmed stump carcinomas at a tertiary care oncology center in Egypt. The demographic, surgical, and pathological data were collected and patients underwent radical surgery with an intent of organ preservation guided by margin negativity. The pathologic data were correlated with the postoperative mortality. Correlation coefficients were calculated for simple correlation and regression analysis was used to investigate the independent predictors of survival. Pelvic exenteration was conducted in 30/60 (50%), while wide local excision with safety margins was possible in 26/60 (43%) and in two cases, resection was precluded. Mean hospital stay in days was 19 ± 9 (range 4-61). Overall operative morbidity was 83.3% (50/60). Perioperative mortality was 6.7% (4/60). Five-year disease-free survival was 40% (24/60). Five-year overall survival was 50% (30/60). The resection margin status and the perioperative therapy were independent prognostic factors of DFS (p = 0.003 and 0.02, respectively. Only the resection margin status was significantly associated with overall survival (p = 0.009). There was no increased mortality with introduction of more conservative surgical approaches. The resection margin status is the most important determinant of recurrence free and overall survivals. © Indian Association of Surgical Oncology 2017.

Entities:  

Keywords:  Carcinoma; Postoperative mortality; Stump; Surgery

Year:  2017        PMID: 36118410      PMCID: PMC9478067          DOI: 10.1007/s13193-017-0640-7

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  15 in total

1.  Indications for primary and secondary exenterations in patients with cervical cancer.

Authors:  Simone Marnitz; Christhardt Köhler; Marianne Müller; Katja Behrens; Kati Hasenbein; Achim Schneider
Journal:  Gynecol Oncol       Date:  2006-08-04       Impact factor: 5.482

2.  Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer.

Authors:  E J Roos; M A Van Eijkeren; T A Boon; A P M Heintz
Journal:  Int J Gynecol Cancer       Date:  2005 Jul-Aug       Impact factor: 3.437

3.  Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.

Authors:  M C Fleisch; P Pantke; M W Beckmann; H G Schnuerch; R Ackermann; M O Grimm; H G Bender; P Dall
Journal:  J Surg Oncol       Date:  2007-05-01       Impact factor: 3.454

4.  Phase II trial of radical surgery for locally advanced pelvic neoplasia.

Authors:  S R Bramhall; J D Harrison; A Burton; D M Wallace; K K Chan; G Harrison; A White; J W Fielding
Journal:  Br J Surg       Date:  1999-06       Impact factor: 6.939

5.  Pelvic exenterations for gynecological malignancies: a study of 36 cases.

Authors:  Manpreet Kaur; Steven Joniau; André D'Hoore; Ben Van Calster; Erik Van Limbergen; Karin Leunen; Freddy Penninckx; Hendrik Van Poppel; Frederic Amant; Ignace Vergote
Journal:  Int J Gynecol Cancer       Date:  2012-06       Impact factor: 3.437

6.  Pelvic exenterations for gynecological malignancies: twenty-year experience at Roswell Park Cancer Institute.

Authors:  S Sharma; K Odunsi; D Driscoll; S Lele
Journal:  Int J Gynecol Cancer       Date:  2005 May-Jun       Impact factor: 3.437

7.  Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

Authors:  David H Moore; John A Blessing; Richard P McQuellon; Howard T Thaler; David Cella; Jo Benda; David S Miller; George Olt; Stephanie King; John F Boggess; Thomas F Rocereto
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

8.  Primary pelvic exenteration in cervical cancer patients.

Authors:  Laszlo Ungar; Laszlo Palfalvi; Zoltan Novak
Journal:  Gynecol Oncol       Date:  2008-09-05       Impact factor: 5.482

9.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

10.  Pelvic exenteration for recurrent cervical cancer: ten-year experience at National Cancer Center in Korea.

Authors:  Heon Jong Yoo; Myong Cheol Lim; Sang-Soo Seo; Sokbom Kang; Chong Woo Yoo; Joo-Young Kim; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.